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Abstract
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The African trypanosome, Trypanosoma brucei spp., is a paradigm for antigenic variation, the
orchestrated alteration of cell surface molecules to evade host immunity. The parasite elicits robust
antibody-mediated immune responses to its Variant Surface Glycoprotein (VSG) coat, but evades
immune clearance by repeatedly accessing a large genetic VSG repertoire and “switching” to
antigenically distinct VSGs. This persistent immune evasion has been ascribed exclusively to
amino acid variance on the VSG surface presented by a conserved underlying protein architecture.
We establish here that this model does not account for the scope of VSG structural and
biochemical diversity. The 1.4Å resolution crystal structure of variant VSG3 manifests heretofore
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unappreciated divergence in the tertiary fold and oligomeric state. The structure also reveals an Olinked carbohydrate on the top surface of VSG3, a modification previously unknown in African
trypanosomes. Mass spectrometric analysis indicates that this O-glycosylation site is
heterogeneously occupied in VSG3 by 0 to 3 hexose residues and is also present in other VSGs.
We demonstrate that this O-glycosylation increases parasite virulence by impairing the generation
of protective immunity. These data alter the paradigm of antigenic variation by the African
trypanosome, expanding VSG variability beyond amino acid sequence to include surface posttranslational modifications with immunomodulatory impact.
Antigenic variation, or the diversification of expressed surface antigens during the course of
infection, is a microbial survival strategy exemplified by the African trypanosome
(Trypanosoma brucei spp.), the causative agent of African sleeping sickness in humans and
nagana in livestock. Central to this immune-evasion strategy is the Variant Surface
Glycoprotein (VSG) coat of ~10 million molecules that densely covers the organism in its
mammalian-infectious forms. The VSG coat elicits a robust antibody response, which the
parasite evades by “switching” to a new, antigenically distinct variant. The VSG-antibody
interaction thus represents the central molecular interface between the T. brucei pathogen
and its host, resulting in observable peaks and valleys of parasitemia that are the repeated
outcome of cycles of VSG switching, antibody generation, and parasite killing1.
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Despite the centrality of the VSG-antibody interface, key parameters of these interactions
remain poorly characterized, such as how antibodies might bind the dense VSG surface
array, and how the sequence diversity between VSG genes manifests structurally to allow
continual evasion of accumulated antibody responses during infection2, 3. Long-held
assumptions have ascribed the immune-evasive properties of new coats exclusively to
divergence in the amino acid sequence of VSG antigenic surfaces displayed on a scaffold of
conserved overall architecture. This view was first formed nearly three decades ago based on
crystal structures of the N-terminal domains (NTDs) of two VSGs4, 5. These early structural
analyses revealed three key features: (i) a general conservation of architecture consisting of a
two-lobed, “dumbbell” arrangement, the “top” (facing away from the pathogen) and
“bottom” regions separated by an elongated 3-helix bundle (Fig. 1a), (ii) the VSGs formed
homodimers, and (iii) despite alignment in the three-dimensional folds of these molecules
(particularly in the core helical bundle), their surface properties varied considerably,
consistent with the generation of immunologically distinct entities.
Structural information and VSG sequence alignments have been used to allocate VSG Nterminal domains to different classes based on the presence of numerous analogous cysteine
disulfides6. The two early VSG structures, VSG2 (also termed MITat1.2 and VSG221) and
ILTat1.24, and a newer structure published during review of this manuscript (VSG M1.1,
which is highly homologous to VSG27) all belong to “class A”. Given the depth of the
genomic archive and the substantial diversity within VSGs even at the level of primary
sequence, it seemed unlikely that the three structures published to date would exhaustively
cover variation in VSG protein space.
Here, we present the crystal structure of the NTD of a common “Class B” variant, VSG3
(also termed MITat1.3 and VSG224), which contains several distinct structural and
Nat Microbiol. Author manuscript; available in PMC 2019 January 09.
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biochemical features as compared to previously published VSGs. Most notably, an
unexpected O-linked glycan was identified in the VSG3 crystal structure at residue S317,
located on the top surface of the NTD. Mass spectrometry analyses revealed heterogeneity in
the number of hexoses linked to VSG3 S317, and also that analogous modifications are
present in other Class B VSGs. Finally, mouse infection and antibody binding assays
showed that the VSG3 O-glycan potently increases parasite virulence and impairs the host’s
ability to generate a protective antibody response against trypanosomes expressing a VSG3
surface coat.

Results
Structural and oligomeric divergence in the VSG3 NTD
Preliminary examinations of VSG3 showed that it not only differs markedly at the sequence
level from VSG2, ILTat1.24 and VSG M1.1 but that it also scored poorly against these
structures in structure-based prediction algorithms such as protein “threading”8. Intrigued by
these analyses, we proceeded to crystallize and solve the structure of this variant (Methods
and Supplementary Table 1).
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The 1.4Å resolution crystal structure reveals that although VSG3 shares the overall twolobe, three-helix bundle architecture with the Class A VSGs, there is substantial divergence
in the fold as well as the topology, such as the connectivity of the lower-lobe subdomain
(Fig. 1, Supplementary Fig. 1). Consistent with such variation, the oligomerization state of
VSG3 is also different, existing in solution and the crystal asymmetric unit as a monomer
rather than a dimer (Supplementary Fig. 2)4, 5, 7. Further divergence from previous VSG
structures is found in the number and location of cysteine disulfide bonds in the top lobe of
the protein (Supplementary Fig. 3), including one that anchors an antigenically critical loop
(discussed below), as well as the position and structural context of an N-linked glycan in the
lower lobe (Fig. 2a and Supplementary Fig. 4).
VSG3 is heterogeneously O-glycosylated
A striking feature of the VSG3 structure is an unexpected carbohydrate modification (Fig. 2a
and b). Additional density attached to S317 revealed the presence an O-linked α-glucose
moiety (Fig. 2b). This modification is located on the top surface of VSG3 in an exposed loop
stabilized by flanking cysteines involved in a disulfide bridge (the peptide CTGSASEGLC,
residues 314-323, Fig. 3a), and is therefore likely to be highly accessible to the immune
system.
Mass spectrometric analysis of intact VSG3 by ES-MS before and after digestion with
PNGaseF validated the O-linked α-glucose moiety identified in the crystal structure, and
additionally revealed heterogeneity in the number of O-linked glycans present
(Supplementary Fig. 5). Subsequently, peptide mass analysis by LC-MS/MS confirmed that
the peptide A311-K339 contained 0, 1, 2 or 3 hexose residues (Fig. 3b), and the MS/MS
product ion spectra of several peptide glycoforms further defined the O-glycosylation site as
S317 (Supplementary Fig. 6). Together, these data strongly suggest that there is a
heterogeneous chain of 0-3 hexoses attached to S317. Based on the ES-MS spectra
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(Supplementary Fig. 5a and b), we estimate the proportions of the 0, 1, 2 and 3 hexose
glycoforms at 8%, 33%, 37%, and 22%, respectively. No evidence of additional
glycosylation of serines or threonines was observed.

Europe PMC Funders Author Manuscripts

While the modification of serine and threonine residues by O- and phosphodiester-linked
carbohydrate chains is known for other kinetoplastids9, such modifications have not been
previously described in T. brucei. To our knowledge, this is also the first description of a
Glcα1-O-Ser linkage in any organism, although Glcβ1-O-Ser linkages are known10. In
addition, no carbohydrate of any kind has been previously shown to occur on the top surface
of any VSG.
Other VSGs display analogous O-linked glycans
To assess the prevalence of surface O-linked glycosylation, we compiled a list of VSGs from
diverse genomic locations11 with N-terminal domains that threaded to VSG3 and contained
cysteine-flanked, serine- or threonine-containing loops analogous to the glycosylated loop in
VSG3. A subset of this list is shown in Fig 3c. We then analyzed two of these: VSG11 and
VSG615. Additionally, we examined VSG21, which fails to thread to VSG3. Mass
spectrometric analysis showed that both VSG11 and VSG615 possessed heterogeneous Olinked hexose modifications analogous to those found in VSG3 (Fig. 3d and e), whereas
VSG21 did not. These data suggest that surface O-linked glycosylation could be a
widespread VSG modification present throughout trypanosome infections.
The VSG3 O-glycan enhances parasite virulence
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Because of its central placement on the top surface of VSG3, we hypothesized that the Olinked glycan might constitute a critical antigenic determinant. To test this conjecture, we
genetically engineered isogenic trypanosome strains that carried either a wild type VSG3
(VSG3WT) coat or a VSG3 coat with a S317A point mutation (VSG3S317A, which cannot be
O-glycosylated). This was achieved by knocking these genes into a VSG2 expression site,
replacing the active VSG2 gene (Methods and Supplementary Fig. 7). We then used these
strains to infect naïve C57BL/6 mice.
The polyclonal antibodies that mediate T. brucei clearance are of IgM-class and directed
solely against exposed epitopes of parasite-bound VSG12. To compare the ability of the two
isogenic strains to evade this IgM response, we focused on the first peak of parasitemia (up
to day 9 post infection). During this period, outgrowth of the VSG3WT/S317A-expressing
trypanosomes occurs, and mice either succumb to infection or clear the parasite population,
leaving only those cells that have switched expression to a new VSG. We observed that all
VSG3WT-infected animals succumbed to infection during the first peak (Fig. 4a). In
contrast, all but one of the VSG3S317A-infected animals survived the first peak, having
cleared the VSG3S317A-expressing trypanosomes by day 8. Late mortality events (after day
10) in the VSG3S317A mouse group resulted from outgrowth of parasites which had
switched expression to other VSGs. This robust differential in virulence was reproducible in
two independent clone sets (Data from the two clone sets are combined in Fig. 4a and shown
separately in Supplementary Fig. 8a and c), and in additional infections of a different mouse
strain (CD-1; Supplementary Fig. 8e). We also observed lower peak parasitemia levels in the
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VSG3S317A infections compared to the VSG3WT infections (Fig. 4b, Supplementary Fig. 8b,
d, and f). However, growth curves between the wild type and mutant VSG3 trypanosomes
were similar in vitro (Supplementary Fig. 7b), suggesting that the differences observed in
infection were related to host factors rather than being clone-intrinsic. We therefore reasoned
that our infection data might reflect a role for the VSG3 O-linked glycan chains in inhibiting
the host’s ability to generate a protective antibody response.
VSG3 O-glycosylation impairs host development of protective immunity
To address this hypothesis, we performed additional infection experiments in which mice
were immunized against VSG3WT or VSG3S317A prior to infection (via inoculation with
UV-irradiated parasites—see methods). This protocol was previously shown to yield an
immune response that closely mimics the response to the infective parasite13. We then
challenged these mice via injection of live cognate parasites at day 8 post-immunization and
monitored mouse blood smears for the presence of trypanosomes on days 5-8 postchallenge. As shown in Fig. 4c, non-immunized mice (Fig. 4a and b) uniformly presented
parasitemia by day 5. We found that pre-immunization with VSG3S317A was highly
protective, suppressing detectable outgrowth of cognate VSG3S317A trypanosomes in 83.3%
(10/12) of mice (Fig. 4c). In contrast, pre-immunization with VSG3WT was only marginally
protective against cognate VSG3WT trypanosomes, suppressing outgrowth in 25% (3/12) of
mice. All mice that presented parasitemia either succumbed to infection or cleared the
parasites by day 8. The discrepancy in the protective effect of pre-immunization was also
evident in survival differences between the two mouse groups (Supplementary Fig. 9a).
These results provide evidence that the O-linked glycan chains displayed by VSG3 inhibit
the ability of the host antibody response to mediate parasite clearance.
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To directly examine the effect of the O-glycan chains on the properties of polyclonal IgM
responses, we collected antisera elicited by VSG3WT or VSG3S317A-coated parasites at day
8 post-infection. We then used flow cytometry (FACS) analysis to assess antisera binding in
the context of the intact parasite surface coat (as surface binding is thought to be necessary
and sufficient to predict clearance12). In accordance with our in vivo results, we found that
VSG3WT-elicited antisera exhibited markedly lower binding against VSG3WT
trypanosomes, as compared to VSG3S317A-elicited antisera binding VSG3S317A
trypanosomes (Fig. 4d and e; Supplementary Fig. 9b-f).
Additional analyses of the cross-reactivities of our polyclonal antisera did not suggest a
simple mechanistic explanation as to how the heterogeneous O-glycan chains cause
elicitation of IgM responses that are poorly functional against cognate VSG3WT coats
(Supplementary Fig. 9b-f). VSG3WT-elicited antisera bind VSG3S317A-expressing parasites
well, which weakens the explanation that O-glycosylation simply causes elicitation of
antibodies that are poorly functional. In the reverse combination, VSG3S317A-elicited
antisera also bind VSG3WT-expressing parasites well, indicating that the O-glycosylation is
not broadly able to inhibit antibody binding. These data therefore suggest that the poor
binding of the WT/WT parasite/antisera combination may result from a combined effect of
the heterogeneous O-glycan chains at both the antibody elicitation stage and in the
subsequent antibody-parasite interactions (discussed further below). Despite the apparent
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complexity of the underlying mechanism, the clear and accordant O-glycan-dependent
discrepancies observed in parasite clearance following infection (Fig. 4a), generation of
protective immunity from pre-immunization (Fig. 4c), and cognate antibody binding (Fig. 4e
and f) altogether strongly indicate that the O-glycan chains that decorate VSG3 aid the
parasite in evasion of the host’s humoral immune response.

Europe PMC Funders Author Manuscripts

Discussion
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The African trypanosome presents a fascinating paradigm for persistent immune evasion
through antigenic variation. The discovery of the VSGs and of VSG coat switching
dramatically altered our understanding of African trypanosomiasis and opened vistas for
research into understanding how a pathogen can continuously avoid the ever-adapting
mammalian immune system. Sequence analyses and some structural studies have provided
many key insights into the bases of antigenic diversity between VSGs. However, the results
we present in this study indicate that our understanding of VSG diversity at the protein level
has been (and almost certainly remains) incomplete. We have demonstrated that VSG
structural architecture is more variable than initially appreciated, expanding the VSG
“diversity space” at the level of the protein fold and resulting molecular surfaces. Secondly
and more unexpectedly, we have identified a VSG post translational modification (of a form
previously unidentified in T. brucei) that changes the antigenic character of the VSG and
exhibits potent immunomodulatory effects. The presence of an O-linked glycan also
indicates the existence of an associated biochemical pathway, including an unidentified Oglycosyltransferase. Given the degree to which O-glycosylation of VSG3 increases parasite
virulence and our identification of analogous modifications in other VSGs, further
characterization of this pathway may provide important insights into T. brucei pathogenesis.
Additionally, other unidentified types of VSG modifications could also modulate hostparasite interactions. The possibility of unidentified biochemical diversity highlights the
need for continued examination of VSGs at the protein level, as such examinations may
reveal additional immunomodulatory factors in T. brucei, with potential relevance to other
pathogens or immune interactions.
Regarding the mechanistic basis of the poor functionality of antibodies elicited against wild
type (O-glycosylated) VSG3 (Fig. 4c-e, Supplementary Fig. 9), it is important to first
reiterate that these analyses represent overall functionality of polyclonal antisera. These
antisera are comprised of a multitude of clonal antibodies (of IgM class), each exhibiting
distinct properties. The factors influencing the overall reactivity of the polyclonal antisera
thus include: (1) the binding epitope of each antibody, (2) whether the epitopes overlap with
or are affected by the glycan, and if so, (3) whether the glycan affects each interaction
enough to significantly alter antibody binding, and finally, (4) the abundance of each
monoclonal IgM antibody within the population of antibodies that make up the polyclonal
antisera. The subject of the effects of glycosylation on antibody binding is a poorly
understood area, complicated by the diverse ways glycosylation can alter the antigenic
character of the modified protein. Relevant literature demonstrates that glycosylation of
proteins and peptides can have myriad effects on the binding profile of antibodies that target
regions in the vicinity of the glycan(s), extending beyond simple exposure or occlusion of
epitopes (reviewed in 14). An individual antibody raised against a glycoprotein may have
Nat Microbiol. Author manuscript; available in PMC 2019 January 09.
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unaffected, increased, or decreased binding affinity based on the presence or absence of the
glycan, the length and composition of the glycan chain, and “allosteric” effects of the glycan
on the structural conformation of the surrounding peptidic regions (i.e. the affected epitope
need not actually include the glycan). The impact of differential glycosylation can vary
dramatically and unpredictably for individual antibodies 15.

Europe PMC Funders Author Manuscripts

The fact that VSG3 is variably modified with a chain of zero to three O-linked hexoses may
also suggest that display of a heterogeneously glycosylated surface can impair immune
function. Heterogeneous O-glycosylation of VSG3 would be expected to produce,
minimally, four antigenically variable entities on the trypanosome surface (one for each
hexose chain length, ignoring the possibility of multiple conformers for each chain). These
multiple glycoforms would therefore present a more diverse set of epitopes for antibody
elicitation and a less homogenous surface for antibody binding. Furthermore, IgM antibodies
are particularly sensitive to epitope density because their binding is typically dependent on
polyvalent interactions. For T. brucei specifically, effective IgM binding and trypanosome
clearance have been demonstrated to require a critical density of cognate VSGs on the
trypanosome surface13. The presence of various glycoforms on a VSG3WT coat could
reduce the effective densities of any epitopes altered by glycosylation. In contrast, a
VSG3S317A coat would be comparatively homogenous and potentially more amenable to
binding for IgMs with certain specificities.
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Overall, because of the complexity of the system and the quantity of unknown variables, it is
impossible to predict a priori the prevalence or proportions of elicited antibodies in our
antisera with given binding epitopes, glycoform specificities, affinities, and avidities, but
these are some of the factors that underlie our binding results in aggregate. The mechanisms
contributing to our results could be further examined by isolating a set of monoclonal
antibodies from the polyclonal responses and testing their binding properties against
different VSG3 glycoforms, or potentially VSG3-derived peptide glycoforms. Importantly
however, the binding effects observed likely depend on multiple epitopes and the overall
structure and packing of VSGs in the surface coat. Such studies could improve our
understanding the impact of glycosylation on the antibody response, a topic with relevance
far beyond T. brucei infection.
In summary, our data demonstrate unexpected antigenic variation in T. brucei VSG-coats
that cannot be predicted by primary sequence analysis. Beyond significant additional
variation in the protein fold, the high-resolution structure of VSG3 reveals an unanticipated
(and potentially widespread) post-translational modification on the VSG surface that
potently enhances parasite immune evasion. Antigenic variation in the African trypanosome
therefore includes multiple overlapping immune evasion strategies: amino acid divergence,
heterogeneous surface glycosylation, and perhaps additional variance yet to be uncovered.

Methods
Purification of VSGs

T. brucei expressing VSG2, VSG3, VSG3-S371A mutant, VSG11, VSG21, or VSG615
were cultured in vitro in HMI-916 media. Cells were pelleted and then lysed in 0.2mM
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ZnCl2, according to established protocols17. This lysis mixture was centrifuged, and the
pellet containing the membrane material was re-suspended in pre-warmed (40°C) 10mM
phosphate buffer. This enabled activation of endogenous lipases and resulted in the efficient
release of surface VSG protein from the membrane. Following a second centrifugation,
supernatant containing VSG3 protein was loaded onto an anion exchange column (Qsepharose Fast-Flow, GE Healthcare), which had been equilibrated with 10mM phosphate
buffer. Two passes through this column resulted in the C-terminal truncation of VSG3 (but
not VSG2), presumably due to cleavage by endogenous proteases. This C-terminally
truncated VSG3 was more stable than full length VSG3 and was used for crystallization.
Further purification steps for VSG3 include one or, if necessary, two runs over a gel
filtration column (Superdex 200, GE Healthcare) in 10mM HEPES pH 7.5 ((4-(2hydroxyethyl)-1-piperazineethanesulfonic acid)), 150 mM sodium chloride (NaCl). Aliquots
from the gel filtrations runs were subjected to SDS-PAGE analysis for visual inspection.
Crystallization and Structural Determination
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For crystallization, the purified VSG3 N-terminal domain was concentrated to 2mg/ml in a
buffer containing 10mM HEPES pH 7.5, 150mM NaCl. Native crystals were grown by
vapor diffusion using hanging drops formed from mixing a 1:1 volume ratio of the protein
with an equilibration buffer consisting of 16-22% polyethylene glycol (PEG) molecular
weight 3350 Da, 200-325mM NaCl, and 100mM Tris pH 8.2
(tris(hydroxymethyl)aminomethane). For cryoprotection, crystals were transferred directly
into a buffer with a 25% PEG 3350 Da, 300mM NaCl, 100m Tris pH 8.2, 10% glycerol, and
flash-cooled immediately afterward to 100K (-173.15°C). Crystals formed in the space
group I23 with a single VSG3 monomer in the asymmetric unit. For phase determination,
crystals were grown in similar conditions in which NaCl was replaced with sodium bromide
(18-22% PEG 3350 Da, 275-400mM sodium bromide, 100mM Tris pH 8.2). Prior to flashfreezing, those crystals were transferred into cryoprotection buffers (25% PEG 3350 Da,
50mM Tris pH 8.2, 5% glycerol) containing stepwise increasing concentration of sodium
bromide from 0.5M to 2M.
Data were collected at Advanced Photon Source (APS) at Argonne National Laboratory at
beamline 24-ID-C and processed onsite through the RAPD software pipeline18, 19, 20, 21,
22. Bromine soaked crystals were collected at a wavelength of 0.9194Å and the structure
solved by SAD (Single-wavelength Anomalous Dispersion) from the anomalous signal due
to 28 partially ordered bromine ions using the SHELX suite23. A partial model of the
bromine-soaked protein was built by the PHENIX suite24. This model was then used in arp/
wARP25, 26 as a starting model for automated building against the native data to 1.4Å
resolution. Several cycles of automated building with arp/wARP, refinement with
REFMAC27, 28, and manual inspection and model building led to a final model with and R/
Rfree of 13.0%/16.9%. Two carbohydrates are present in the model – an N-linked
Man2GlcNAc2 to N67 and an O-linked Glc to S317.
Digestion, de-N-Glycosylation and Mass Spectrometry
Preparation of N-glycopeptides—Purified VSG3 (400 μg) was denatured and reduced
(200 μl 10 mM sodium phosphate, pH 8.0, 8 M urea, 40 mM dithiothreitol (DTT), 2 h, room
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temperature (RT)) and S-alkylated by adjusting to 100 mM iodoacetamide (IAA), 1 h, RT, in
the dark. Unreacted IAA was quenched by the addition of 4 μl of 1M DTT and sample
adjusted to 400 μl containing 2 mM calcium acetate 80 μg Pronase (Sigma-Aldrich). After
digestion for 24 h, RT the Pronase glycopeptides were enriched using cotton wool
hydrophilic interaction liquid chromatography prior to reverse phase liquid
chromatography29 tandem mass spectrometry (LC-MS/MS).
Preparation of O-glycopeptides—Purified VSG3 (50 μg in 25 μl 10 mM sodium
phosphate, pH 8) was reduced (10 mM DTT, 85 °C, 20 min), S-alkylated (25 mM IAA, 1h,
RT in the dark), diluted with an equal volume of 2 x GluC buffer and digested with 1:25
(w/w) endoproteinase GluC (New England BioLabs) for 24 h, 37 °C, with shaking. The
GluC fragments were separated using NuPAGE 4-12% Bis-Tris protein gels (Invitrogen),
stained with Coomassie Brilliant Blue (Thermo Scientific) and the 17 kDa fragment was
excised and subjected to in-gel trypsin digestion for LC-MS/MS analysis.
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LC-MS/MS analysis of glycopeptides—The LC was an Ultimate U3000 Nano LC
System (Dionex) fitted with a C18 trap (PepMap nanoViper, Thermo Scientific) and
resolving column (PepMap RSLC) with inner diameters of 100 and 75 μm and lengths of 2
and 50 cm, respectively. Mobile phases were 0.1% formic acid in 2% acetonitrile (solvent A)
and 0.08% formic acid in 80% acetonitrile (solvent B). Samples were loaded in solvent A
and eluted as follows: 0% B for 5 min, gradient to 40% B in 122 min and to 98% B in 10
min held at 98% B for 20 min followed by 20 min re-equilibration with 2% B. The LC
system was coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific)
equipped with an Easy Spray ion source and operated in positive ion mode. The spray
voltage was 2 kV and the full scans were acquired in a Fourier transform MS mass analyser
over m/z 335-1800 at a resolution of 60,000. The MS/MS analyses were performed under
data-dependent mode to fragment the top 15 precursors using collision induced dissociation
(CID). The raw files, converted to mgf format by MSConvert
(proteowizard.sourceforge.net), were searched against the VSG3 protein sequence using the
Mascot software (v.2.4.0, Matrix Science Inc., Boston, MA) with the parameters set as
follows: peptide tolerance, 5 ppm; MS/MS tolerance, 0.5 Da; enzyme, trypsin; one missed
cleavage allowed; and fixed carbamidomethyl modifications of cysteines. Oxidation of
methionine and serine conversion to de-hydro alanine were used as variable modifications.
LC-MS analysis of intact and de-N-glycosylated VSG3—VSG3 (50 μg) was
denatured in 1% sodium dodecyl sulphate for 10 min at 95 °C and then digested with 2500
units of glycerol free N-glycosidase F (PNGaseF, NEB) in 1% n-octyl-β-D-glucopyranoside
for 24 h at 37 °C. The de-N-glycosylated product was precipitated in 10% trichloroacetic
acid for 24 h at 4 °C, collected by centrifugation (16 x 000 g, 20 min, 4 °C), washed with
cold acetone, air dried and redissolved in 1% formic acid. A control (non-treated) VSG3
sample was similarly TCA-precipitated and redissolved in 1% formic acid. The samples
were analysed by LC-MS using an Agilent 1200 System fitted with a C8 column (Agilent),
25μm ID, 360 mm long. The mobile phases were the same as above. Samples were loaded in
solvent A and eluted as follows: 7% B for 8 min, gradient to 25% B in 25 min and to 60% B
in 48 min held at 60% B for 10 min followed by 10 min re-equilibration with 7% B. The LC
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was coupled to an Agilent 6520 Q-Tof mass spectrometer. The spray voltage was 1.7 kV and
the ion transfer tube was set at 360 °C. MS scans were collected over m/z 335-3200 and
spectra were deconvoluted using the Maximum Entropy software with the settings mass
range 35-45k; mass step, 1.0 Da; S/N threshold, 30; adduct, proton; average mass, 90% peak
height; maximum consecutive charge state, 5; and minimum protein fit score of 8.
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Cloning of VSG3 and VSG3-S317A knock-in vectors pKI224 and pKI224-S317A
Plasmid cloning was performed as follows: first, the wild type VSG3 gene was amplified
from trypanosomal genomic DNA (Lister427) into a pGEM subcloning vector (Promega
A1360), and the S317A mutation was introduced by QuickChange PCR. Wild type and
mutant VSG3 genes were then cloned into the vector pUB39 30 (replacing VSG117 in the
original vector via HindIII and BamHI sites) to create pSUN7 and pSUN8. VSG3 and
VSG3-S317A were amplified from pSUN7 and pSUN8, respectively, using primers
224_BsiWI_For (GCGACACGTACGCGGCATGCAAGCGGCAGCA) and 224_AvrII_Rev
(AATTAACCTAGGGGGCAATTCCAGCTGTC) (these PCR fragments contained the WT/
S317A VSG3 coding regions along with the surrounding VSG117 5’ and 3’ UTRs from the
pUB39 vector). The backbone vector pSY37F1D-CTR-BSD was digested with BsiWI and
SpeI, and the larger fragment was isolated by gel purification. VSG3 and VSG3-S317A PCR
fragments were digested with BsiWI and AvrII and ligated into the pSY37F1D-CTR-BSD
fragment, resulting in final plasmids pKI224 and pKI224-S317A, respectively.
Generation of VSG3WT and VSG3S317A -expressing T. brucei
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The wild type VSG3 and VSG3-S371A point mutant genes were transfected into
trypanosomes by means of the previously established pSY37F1D-CTR-BSD vector13.This
vector contains a blasticidin-resistance gene (BSD) cassette and allows a “knock-in”
transfection in which the VSG gene included in the vector replaces the endogenous VSG2
gene in the telomeric Bloodstream-form Expression Site 1 (BES1) of the Lister427 genome
(see diagram, Supplementary Fig. 7a). First, the wild type VSG3 and VSG-S317A point
mutant genes were cloned into the PSY37F1D-CTR-BSD vector backbone to create
plasmids pKI224 and pKI224-S317A, respectively. These plasmids were then linearized
with XhoI and transfected into a parental clone expressing VSG2 via the Amaxa
nucleofector protocol as previously described 31. BSD resistant clones were selected based
on expression of VSG3 (by FACS) and counterselected for dual expressors (which coexpressed VSG2; also by FACS), using monoclonal antibodies to VSG2 and VSG3. VSG2
counterselection was used to eliminate a subset of clones which integrated the VSG cassette
ectopically. Two sets of clones were generated. Transfection of VSG3 and VSG3-S317A
into the Lister 427 “single marker” cell line32 produced clones KI.VSG3WT-1 and
KI.VSG3S317A-1, respectively. Transfection of VSG3 and VSG3-S317A into a different
VSG2-expressing Lister 427 cell line (GPIPLC null, 30) produced clones KI.VSG3WT-2 and
KI.VSG3S317A-2, respectively. KI.VSG3WT-2 and KI.VSG3S317A-2 were generated on a
GPIPLC-/- background. The lack of a GPI-PLC gene does not affect parasite virulence or
the course of parasitemia 30 and consequently should not affect interpretation of the mouse
infection results shown. The presence of the single point mutation within VSG3S317A was
verified in the KI.VSG3S317A clones through RT-PCR amplification and sequencing.
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Mouse Infection Assays
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For Fig. 4a and b, groups of C57BL/6J or CD-1 mice were infected via i.p. injection of 100
live trypanosomes, expressing either VSG3WT or VSG3S317A. For Fig. 4c and
Supplementary Fig. 9a, immunization-challenge experiments were performed as previously
described 13 using C57BL/6J mice. For immunization, mice received an i.p. injection with
2-3 x 106 UV-irradiated trypanosomes (KI.VSG3WT-2 or KI.VSG3S317A-2; these clones
lack the endogenous lipase GPI-PLC, and therefore retain intact VSG coats following
irradiation30) in 100ul HMI-9, and an identical repeat injection 3 days later. The subsequent
challenge injection was administered 8 days after the initial immunization, and consisted of
100 live trypanosomes (as in the Fig. 4a and b experiments). For all infection experiments,
mouse survival was assessed daily, and parasitemia was monitored starting on day 4 or 5 by
blood-smear (blood from mouse tail clippings examined under a microscope for the presence
of trypanosomes) or by counting parasite numbers using a hemocytometer. For Fig 4c, mice
were permanently scored as “confirmed parasitemia” when parasites were first identified by
blood smear, regardless of whether parasitemia subsequently fell to undetectable levels. All
mice were wild type males or females, aged 6-9 weeks at experiment start (Jackson
Laboratory). We did not have an a priori, pre-specified effect size from which to
preemptively determine an appropriate sample size for our mouse infection experiments, but
the sample sizes were determined to be large enough to ensure proper statistical analyses and
reproducibility. Mice were assumed to be sufficiently randomized by Jackson Laboratory
and no additional randomization was performed. Experimenters were not blinded to mouse
group allocation, but measurements (survival assessment, parasitemia counts, FACS MFI)
were not subjective. All animal experiments were approved by Rockefeller University’s
institutional animal care and use committee under protocol #16894.
Elicitation of VSG3WT and VSG3S317A-specific polyclonal IgM antisera
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C57BL/6J mice were injected i.p. with 1 x 103 VSG3WT or VSG3S317A-expressing
trypanosomes in HMI-9 (three mice each). After 4 days, infections were cleared with 250ug
berenil/mouse injected i.p., and berenil treatment was repeated after 24 hours. Clearance was
necessary to prevent VSG3WT-infected animals from succumbing to infection prior to
developing significant antibody titers. On day 8 post-injection, blood was collected via
cardiac puncture, and serum was separated from whole blood using Microtainer serum
collection tubes (BD 365967).
FACS analyses to determine IgM binding
All samples, solutions, and incubation steps were at 4°C or on ice to prohibit antibody
internalization during sample preparation. 106 VSG3WT or VSG3S317A-expressing
trypanosomes were isolated from culture, resuspended in HMI-9 containing dilutions of
VSG3WT or VSG3S317A-specific polyclonal IgM antisera (see above), and incubated for 10
min. Cells were washed once with HMI-9, then incubated with 1:1000 dilution of goat antimouse IgM-FITC (SouthernBiotech 1021-02) in HMI-9 for 10 min. Cells were washed once
again with HMI-9, resuspended in HMI-9 containing 500ng/ml Propidium Iodide (BD
556463) (for exclusion of dead cells from analysis), and analyzed using a BD-FACSCalibur
(Fig. 4c) or BD-LSRII flow cytometer (Fig. 4d) and FlowJo software (Treestar).
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Substantial structural divergence between VSGs.
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(a) Comparison of monomeric VSG structures. VSG2 (MITat1.2), ILTat1.24 and VSG3 are
shown as ribbon diagrams colored by six structurally conserved elements: the three helices
of the stalk-like bundle (three shades of blue for each individual helix, H1-H3), the top and
bottom lobes (red and salmon, respectively), and a conserved, elongated loop in the top lobe
(purple). (b) Superposition of the three monomers, colored on the left by the schema
described in (a) and on the right by individual protein as indicated in the labeling.
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Fig. 2. Structural identification of O-linked Carbohydrate on VSG3 Surface.
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(a) Left is a superposition of VSG3 (blue) and VSG2 (gold) with conserved purple “top
loop.” The GlcNAc2 cores of the lower lobe N-linked glycans of the two VSGs are
displayed as red space-filling atoms (coloring of arrows pointing to the glycans indicates to
which VSG they belong). On the top surface of the upper lobe is a red space-filling
representation of the α-glucose moiety attached to S317 of VSG3. A 90-degree rotation of
the left model is rendered with molecular surfaces (blue for VSG3 protein, red for a spacefilling representation of the glucose). (b) 1.4 angstrom resolution electron density map from
the refined model of VSG3 clipped to the volume around the modeled glucose (Glc). S317 is
shown connected to a ribbon diagram representation of the protein main chain (blue).
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Fig. 3. Identification of heterogeneous O-linked glycans in surface loops of multiple VSGs.

(a) Cysteine-flanked glycan loop of VSG3 with the loop in yellow and the disulfide-bridged
cysteines shown as yellow spheres and labeled, S317 shown as a stick model in orange, and
the glucose atoms in red. (b) Extracted ion chromatogram showing the elution profiles of [M
+3H]3+ ions (m/z 1035.1, 1089.1, 1143.1 and 1197.1) for the A311 to K339 peptide of
VSG3 containing 0, 1, 2 and 3 hexose residues, respectively. These elute by reversed-phase
HPLC from most hydrophilic to least hydrophilic with decreasing numbers of sugar residues
attached. This experiment was performed once. (c) Comparison of hypothesized “O-linked
glycan” loops in additional VSGs. O-glycosylation was examined and confirmed for three
VSGs (boxed in red): VSG3, VSG11, and VSG615. (d) and (e) are similar to (b) showing
the extracted ion chromatogram results for VSG11 and VSG615, respectively, with the
determined (VSG11) and the proposed (VSG615) modified serine residues indicated within
the relevant peptide (the MS/MS data of the VSG615 glycopeptides did not allow
unambiguous assignment of S292 as the unique O-glycosylation site, and thus T291 and
S297 could also potentially be sites of modification). These experiments were performed
twice each with similar results.
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Fig. 4. Presence of O-linked glycan impairs immune function.

(a) Survival of mice infected with trypanosomes expressing VSG3WT or non-glycoslyated
mutant VSG3S317A (n = 15 mice/group). Shaded regions represent sequential “peaks” of
parasitemia. Data are combined results from two experiments with independent clone sets
and representative of results within each set (n = 5 or 10 mice/group, see Supplementary Fig.
8). Statistical analysis was performed using a two-sided log-rank test (Mantel-Cox). (b)
Parasitemia levels at day 5 post-infection. Data are combined from two independent clone
sets as in (a) (separated in Supplementary Fig. 8). Statistical values were calculated by twosided Mann-Whitney test; bars represent median and interquartile range (c) Emergence of
parasitemia in non-immunized (N.I.) and pre-immunized mice. N.I. data are from infections
shown in (a) and (b) (n = 15 mice/group). Pre-immunized mice (n = 12 mice/group) were
inoculated with UV-irradiated trypanosomes expressing VSG3WT or VSG3S317A (Imm. WT
or S317A, respectively) on days -8 and -5 relative to challenge. Challenge injection
contained live parasites expressing the same VSG to which the mice were immunized. Mice
were permanently scored as “parasitemia confirmed” when parasites were first detected via
blood smear. (d) Comparison of VSG3WT or VSG3S317A-elicited IgM antisera (a.s.) binding
to live VSG3WT or VSG3S317A-expressing parasites (par.). Binding was measured by FACS
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analysis using dilutions of primary antisera, visualized after counterstaining with FITClabeled anti-mouse-IgM, and reported as mean fluorescence intensity (MFI). Data are shown
for one antiserum sample per VSG type. This experiment was performed twice with similar
results. (e) Similar to (d) but with a single dilution (1:2000) of distinct antisera, elicited by
infection of multiple mice (n = 3 independent antisera/VSG type; error bars represent mean
± SD). Statistical values were calculated by two-sided t-test, assuming normal distribution,
and similarity of variances was confirmed by F test. For additional statistical analyses see
Supplementary Fig. 9. For (d) the dotted line represents background MFI. This experiment
was performed once.
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